Emcure Pharmaceuticals Limited IPO

Company Background

Incorporated in 1981, Emcure Pharmaceuticals Limited is a prominent Indian pharmaceutical company engaged in developing, manufacturing, and global marketing a wide array of pharmaceutical products. These products span several major therapeutic areas, with the company establishing a significant market presence over the years. Market Position and Performance

As of MAT September 2023, Emcure Pharmaceuticals is ranked 13th in domestic sales among pharmaceutical companies in India. The company holds the 4th largest market share in its covered markets for the same period. Emcure is the leading pharmaceutical company in the gynaecology and HIV antiviral therapeutic areas for MAT September 2023. Manufacturing Capabilities

Emcure Pharmaceuticals operates 13 manufacturing facilities in India, capable of producing a variety of pharmaceutical and biopharmaceutical products. These facilities can manufacture pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.

Distribution Network

As of September 30, 2023, Emcure’s marketing and distribution network in India is supported by over 5,000 field personnel who regularly interact with healthcare providers. The distribution network includes over 5,000 stockists, served by 37 carry-and-forward agents. Objectives of the Issue

1. Repayment and prepayment of outstanding borrowings

2. General corporate purposes

Emcure Pharma IPO IPO Dates: 03 to 05 July 2024

Price Band: ₹960 to ₹1008 per share

Lot Size: 14 shares

Total Issue Size: ₹1952.03 Crores

Retail Quota: 35%

GMP: 30% (For informational purposes only)

Allotment Link

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.